Clinical Trial Update: A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated ALIMTA (pemetrexed) plus gemcitabine in locally advanced or metastatic urothelial carcinoma and has completed the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Urologic Neoplasms | Phase 2 | Status: COMPLETED